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Background: In the present study factors affecting survival and toxicity in cerebral metastasized patients treated
with stereotactic radiosurgery (SRS) were analyzed with special focus on radiation necrosis.
Patients and methods: 340 patients with 1–3 cerebral metastases having been treated with SRS were
retrospectively analyzed. Radiation necrosis was diagnosed by MRI und PET imaging. Univariate and multivariate
analysis using a Cox proportional hazards regression model and log-rank test were performed to determine the
prognostic value of treatment-related and individual factors for outcome and SRS-related complications.
Results: Median overall survival was 282 days and median follow-up 721 days. 44% of patients received WBRT during
the course of disease. Concerning univariate analysis a significant difference in overall survival was found for Karnofsky
Performance Status (KPS≤ 70: 122 days; KPS > 70: 342 days), for RPA (recursive partitioning analysis) class (RPA class I:
1800 days; RPA class II: 281 days; RPA class III: 130 days), irradiated volume (≤2.5 ml: 354 days; > 2.5 ml: 234 days),
prescribed dose (≤18 Gy: 235 days; > 18 Gy: 351 days), gender (male: 235 days; female: 327 days) and whole brain
radiotherapy (+WBRT: 341 days/-WBRT: 231 days). In multivariate analysis significance was confirmed for KPS, RPA class
and gender. MRI and clinical symptoms suggested radiation necrosis in 21 patients after SRS +/− whole brain radiotherapy
(WBRT). In five patients clinically relevant radiation necrosis was confirmed by PET imaging.
Conclusions: SRS alone or in combination with WBRT represents a feasible option as initial treatment for patients with
brain metastases; however a significant subset of patients may develop neurological complications. Performance status,
RPA class and gender were identified to predict improved survival in cerebral metastasized patients.
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Cerebral metastases are diagnosed in about 30% of pa-
tients with advanced tumors [1,2]. Lung cancer, breast
cancer and malignant melanoma are the most common
causes for brain metastases. Symptoms depend on localiza-
tion and size including signs of increased intracranial* Correspondence: claus.belka@med.uni-muenchen.de
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article, unless otherwise stated.pressure, headaches, vertigo, nausea and vomiting, paraes-
thesia and seizures.
Patients having more than three brain metastases are
generally treated with whole-brain radiotherapy (WBRT).
Oligometastatic patients with 1–3 lesions have a better
prognosis and are therefore treated more aggressively.
Beside neurosurgical resection stereotactic radiosurgery
(SRS) is an effective treatment option for patients with
1–3 brain metastases [3,4]. For radiation treatment some
studies have shown that SRS alone might be superior
to WBRT alone for survival advantage of RPA class I
patients [5,6]. It cannot be excluded that this effect isntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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radiosurgery.
In three randomized trials additional WBRT showed
even better intracranial tumor control and reduced
neurologic causes of death but failed to improve patients
overall survival and functional independence [7-9]. The
1-year local control rates at the initial tumor site after
neurosurgical resection or SRS +/− WBRT were about
80% [3,4,7,8]. Intracranial relapse occurred more fre-
quently in patients having received SRS or resection
only. In this context WBRT was used more often as a
salvage treatment. The deferred WBRT probably im-
proved the length of the survival and functional inde-
pendence in the observation arm. The latest Cochrane
Analysis of WBRT reported an improved local and dis-
tant brain control but no difference in overall survival
for SRS +WBRT compared to SRS alone [10].
SRS as well as WBRT has a risk for adverse events. Ra-
diation necrosis appears 1–2 years after radiotherapy
(RT) and cognitive decline develops over many years.
For fractionated RT (<2.5 Gy/d) high cumulative doses
are tolerated. Radiation induced necrosis is predicted to
occur in 5% at a biologically effective dose of 120 Gy
[11]. For SRS a correlation between the target volume,
dose and the risk of adverse events has been demon-
strated [12,13]. However the tolerated doses for SRS
show a great range in literature. In dose escalation study
RTOG 90–05 maximum tolerated doses were 24 Gy,
18 Gy, and 15 Gy for tumors ≤ 20 mm, 21–30 mm, and
31–40 mm [14].
The present study was performed to assess factors that
have prognostic relevance on survival in cerebral metas-
tasized patients treated with stereotactic radiosurgery
and to assess side effects with a special focus on radi-
ation induced necrosis.
Patients and methods
Patient data and dose fractionation
Between March 2000 and December 2010 340 patients
with 1–3 cerebral metastases were treated with stereo-
tactic radiosurgery.
Patients with stable systemic disease at the time of
SRS or general cerebral progression during follow-up re-
ceived additional WBRT. The prescribed dose for WBRT
usually was 35 Gy/37.5 Gy in 14/15 fractions of 2.5 Gy
or 30 Gy in 10 fractions of 3 Gy at midline, 5 fractions
per week. Patients showing further single brain metasta-
ses during follow-up, but stable systemic disease, again
were treated with SRS.
Head frames
For stereotactic radiosurgery a Brown-Robert-Wells (BRW)
or Gill-Thomas-Cosman (GTC) stereotactic head frame
was used. While the BRW frame is fixated to the headwith four screws to ensure a definite connection between
cranium and head frame the GTC frame is less invasive by
using dental fixation. Afterwards a planning computed
tomography (CT) with localizer was performed. To ensure
the correct position of the head frame a depth helmet was
used to measure the distance between cranium and sur-
face of the helmet. This control was done before planning
CT and immediately before stereotactic radiosurgery.Radiation planning
For radiation planning and image fusion Radionics Xknife™
was used. The gross tumor volume (GTV) was identified
and delineated in fused image of the CT and the magnetic
resonance imaging (MRI). Due to spherical growth of
brain metastases the clinical target volume (CTV) was set
equivalent to the GTV. Regarding risk structures and ana-
tomical borders expansion of the GTV plus 1–2 mm re-
sulted in the planning target volume (PTV).Dose
Radiation dose was 24 Gy for metastases with a diameter
<20 mm, 18 Gy for metastases between 20–30 mm and
15 Gy for a diameter >30 mm prescribed to the 80% iso-
dose. Due to the geometry of the metastases some pa-
tients received 20 Gy. A modified Linear Accelerator
(Mevatron M/Fa. Siemens) with 6 MV photons was used
for treatment. The PTV was irradiated with three to
eight arcs depending on size and localization.MRI protocol
A T1 weighted contrast enhanced sequence was used to
determine the gross tumor volume. No image tilt (0°)
was allowed. Slice thickness ≤ 3 mm, Inter-Slice-Spacing
0 mm.FET-PET
For PET scan the amino acid [18 F]-fluoro-ethyl-L-tyro-
sine (FET) was used. FET uptake in the tissue was mea-
sured as standardized uptake value (SUV). Maximum
lesion-to-brain ratios (LBRs) were calculated and time–
activity curves were analyzed.Statistics
The patient data was collected between March 2000 and
December 2010. All analyses were performed using the
Statistical Package for Social Sciences (SPSS, Ver. 19.0,
SPSS Inc, Chicago, IL). Survival analyses were based on
Kaplan-Meier estimates, univariate testing was per-
formed by means of the log-rank test and Cox regression
analysis was used to determine hazard ratios as well as
to perform a multivariate analysis. A two-tailed p-value ≤
0.05 was considered significant.
Table 1 Baseline patient characteristics, N = 340,
WBRT – whole brain radiotherapy
Characteristic Patients
Median follow-up 721 days
Sex
• Male 159 (46.8%)
• Female 181 (53.2%)
Median age 62
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Follow-up was regularly performed every three months.
If patients did not keep the appointments, a telephone
follow-up was used. Cerebral staging was done by con-
trast enhanced MRI. If radiation necrosis was suspected,
diagnostics was completed either by FET-PET and/or
brain biopsy, or patients were treated with dexametha-
sone only ex juvantibus. Alternatively a control MRI was
done about 4 weeks later.Age
• < 65 y 208 (61.2%)
• ≥ 65 y 132 (38.8%)
WBRT
• No 189 (55.6%)
• Yes 151 (44.4%)
RPA class
• I 26 (7.7%)
• II 271 (79.7%)
• III 43 (12.6%)
Karnofsky Performance Score
• ≤ 70 82 (24.1%)
• > 70 258 (75.9%)
Number of cerebral metastases
• 1 197 (57.9%)
• 2 101 (29.7%)
• 3 31 (9.1%)
• 4 8 (2.4%)
• 5 2 (0.6%)
• 7 1 (0.3%)Results
Patient characteristics
Between March 2000 and December 2010 340 patients
(159 males and 181 females) with newly diagnosed brain
metastases were treated with SRS (Table 1). The median
age was 62 years. One hundred ninety seven patients
(57.9%) had one metastasis, 101 patients (29.7%) had
two metastases and 31 patients (9.1%) had three metas-
tases. Some patients showing further single brain metas-
tases but stable systemic disease during follow-up were
again treated with SRS. Therefore eight patients had four
metastases, two patients had five metastases and one pa-
tient even had seven metastases in total. The most com-
mon tumor types were lung cancer (55%), malignant
melanoma (14.4%) and breast cancer (12.1%). More than
half of the patients (55.6%) received no additional
WBRT. Referring to the Radiation Therapy Oncology
Group (RTOG) based recursive partitioning analysis
(RPA) 26 patients (7.7%) were RPA class I, 271 patients
(79.7%) RPA class II and 43 patients (12.6%) RPA class III.
Two hundred fifty eight patients (75.9%) had a Karnofsky
Performance Score > 70.Histology
• NSCLC 160 (47.1%)
• SCLC 27 (7.9%)
• Malignant Melanoma 49 (14.4%)
• Breast Cancer 41 (12.1%)
• Renal Cell Carcinoma 20 (5.9%)
• Others 43 (12.6%)
Median radiation volume 1.7 ml
Median dose to the 80% isodose 20 Gy
Radiation necrosis
• Yes 21 (6.2%)
• No 319 (93.8%)Survival data
The median follow-up of all patients was 721 days using
the reverse Kaplan-Meier [15]. The median survival time
after SRS was 282 days; 1-year survival rate was 28.8%
and 2-year survival rate was 10.6%. Survival data after
stereotactic radiosurgery of the cerebral metastases is
shown in Table 2. Univariate analysis of potential
prognostic factors showed a significant difference for
Karnofsky Performance Status (KPS ≤ 70: 122 days; KPS
> 70: 342 days; p < 0.001), for RPA (recursive partitioning
analysis) class (RPA class I: 1800 days; RPA class II:
281 days; RPA class III: 130 days; p < 0.001), irradiated
volume (≤2.5 ml: 354 days; > 2.5 ml: 234 days; p =
0.002), prescribed dose (≤18 Gy: 235 days; > 18 Gy:
351 days; p < 0.001), gender (male: 235 days; female:
327 days; p = 0.013) and whole brain radiotherapy
(+WBRT: 341 days/-WBRT: 231 days; p = 0.049) (Figure 1).
For categorical analysis of volume and dose dependent
overall survival the largest lesion in first irradiation session
was used to categorize patients having more than onemetastasis (median volume 2.5 ml and median dose 18 Gy
for dominant lesion).
Multivariate analysis revealed the following factors to
be statistically significant predictors for survival: the
Karnofsky Performance Status (hazard ratio (HR) 2.19
for KPS ≤ 70 vs. KPS > 70; p < 0.001), RPA (HR 3.61 for
Table 2 Univariate and multivariate analysis on potential prognostic factors for overall survival after stereotactic





Univariate analysis Multivariate analysis





Sex 0.013 0.042 1.31
• Male 159 235 172 – 298
• Female 181 327 274 – 380
• Overall 340 282 232 – 332
WBRT 0.049 ns (0.067) 1.28
• No 189 231 172 – 290
• Yes 151 341 280 – 402
• Overall 340 282 232 – 332
KPS < 0.001 < 0.001 2.19
• ≤ 70 82 122 84 – 160
• > 70 258 342 298 – 386
• Overall 340 282 232 – 332
Histology ns (0.488)
• NSCLC 160 275 218 – 332
• SCLC 27 231 151 – 331
• Melanoma 49 286 201 – 371
• Breast Ca 41 383 153 – 613
• RCC 20 184 0 – 435
• Others 43 265 36 – 582
• Overall 340 282 217 – 494
Age ns (0.1)
• < 65 y 208 306 254 – 358
• ≥ 65 y 132 247 177 – 317
• Overall 340 282 232 – 332
Number of metastases ns (0.764)
• 1 197 268 203 – 333
• 2 101 275 183 – 367
• 3 31 332 0 – 710
• 4 8 467 47 – 905
• 5 2 341 –
• 7 1 834 –
• Overall 340 282 232 – 332
Dose < 0.001 ns
• ≤ 18 Gy 175 235 156 – 314
• > 18 Gy 165 351 255 – 447
340 282 232 – 332
Volume 0.002 ns
• ≤ 2.5 ml 172 354 262 – 446
• > 2.5 ml 168 234 162 – 306
• Overall 340 282 232 – 332
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Table 2 Univariate and multivariate analysis on potential prognostic factors for overall survival after stereotactic
radiosurgery, ns – not significant, CI – confidence interval (Continued)
RPA class < 0.001
• I 26 1800 362 – 3238 < 0.001
• II 271 281 227 – 335 < 0.001 3.61
• III 43 130 17 – 243 0.001 3.85
• Overall 340 282
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I, p < 0.001 for RPA II, p = 0.001 for RPA III) and gender
(HR 1.31 for male vs. female; p = 0.042) (Table 2).
Analysis of radiation necrosis
Radiation necrosis is regarded as the most relevant ad-
verse event after SRS. During follow-up in 21 patients
(6.2%) radiation necrosis was supposed in MRI. The
most common neurologic symptom was dizziness. Two
patients had cerebellar ataxia. Eleven patients received
FET-PET to differentiate between radiation necrosis und
recurrent metastasis (Figure 2). The maximum lesion-
to-brain ratios (LBRs) were higher in patients with re-
current metastases (n = 6; mean LBR = 2.55) than in pa-
tients with radiation necrosis (n = 5; mean LBR = 1.84).
Time–activity curves were assessed in nine patients with
ten cerebral lesions. In five patients early peak of FET
uptake followed by constant decline of uptake was seen
(decreasing kinetics). These were all patients with high
LBRs and were assumed to have recurrent metastasis.
Four of these five patients had brain biopsy or neurosur-
gical resection. In two cases recurrent metastasis was
confirmed histologically, the other patients had necrosis
only. Dynamic evaluation of four patients with low LBRs
showed constantly increasing FET uptake until the end
of acquisition confirming radiation necrosis. Volume
(p = 0.151), prescribed dose (p = 0.236) and fraction-
ated WBRT (p = 0.368) had no influence on radiation
necrosis.
Discussion
The current study was performed to define prognostic
factors for survival and the incidence of radiation necro-
sis in cerebral metastasized patients after treatment with
stereotactic radiosurgery. The median overall survival
was 282 days. Different prognostic factors could be iden-
tified including Karnofsky Performance Status, RPA
class, irradiation volume, prescribed dose, gender and
additional WBRT. Despite WBRT and gender these fac-
tors are well known to correlate with survival prognosis.
RPA classes which were created as a prognostic tool are
defined by age, KPS, presence of extracranial metastases
and control of primary tumor. The overall survival of
patients in the study cohort was 59.2 months for RPAclass I, 9.2 months for RPA class II and 4.3 months for
RPA class III. Compared to other historical groups the
survival time, especially for RPA class I, is rather high.
Sneed et al. reported a median survival time after SRS
alone or SRS +WBRT of 14 and 15.2 months for RPA
class I, 8.2 and 7 months for RPA class II and 5.3 and
5.5 for RPA class III [16]. In our study cohort only a few
patients (7.6%) met criteria for RPA class I and had more
favorable features.
Male patients had a significantly shortened overall sur-
vival compared to females. This could be explained by
the fact that fewer women smoke than men and breast
cancer, which has better prognosis per se, occurred in
women exclusively. Breast cancer as histologic entity
had no significantly improved overall survival. This
could be explained by the limited number of cases.
In categorical analysis high dose (>18 Gy) and small ir-
radiation volume (≤2.5 ml) correlated with prolonged
survival. Both parameters might result in an increased
local control rate with a decreased chance for neuro-
logical cause of death.
The univariate analysis of survival data suggested a
significant survival benefit for patients that had received
a whole-brain radiotherapy (SRS +WBRT: 341 days/SRS
alone: 231 days; p = 0.049). Another retrospective ana-
lysis was associated with a trend towards improved sur-
vival for additional WBRT (median survival time 15.4
versus 8.3 months, p = 0.08) [17].
None of the prospective randomized studies could
confirm these findings: Adding postoperative WBRT
after surgical resection of single metastases prevented
brain recurrence of tumor (18% vs 70%, p < 0.001) and
reduced neurologic cause of death (14% vs 44%, p =
0.003) compared to patients in the observation group.
There was no significant difference between the 2
groups in overall length of survival or the length of time
that patients remained functionally independent [9].
In another randomized trial from Japan 132 patients
with 1 to 4 brain metastases where either treated with
SRS +WBRT (65 patients) or with SRS alone (67 pa-
tients). The median survival time and 1-year survival
rate were 8.0 months and 28% for the SRS group and
7.5 months and 39% for the SRS +WBRT group (p =
0.42). The 1-year local control rate (73% vs. 89%, p =
Figure 1 Kaplan-Meier analysis of overall survival for RPA classes (p < 0.001), KPS (p < 0.001), volume (p = 0.002) and dose (p < 0.001).
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Figure 2 Example of recurrent brain metastasis: the study shows pathologic contrast enhancement on T1-weighted MRI and corresponding
increased [18 F]-FET uptake. While radiation necrosis was suspected in MRI, PET showed a pathologic FET uptake as seen in recurrent metastasis.
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0.003) were better for the combined treatment [7].
The latest prospective trial with 359 patients was pub-
lished in 2011 by Kocher et al. 199 patients received
SRS, 160 patients were treated with surgical resection.
After SRS, 100 patients were allocated to the observation
group, 99 were allocated to WBRT. After surgery, 81 pa-
tients received WBRT while 79 patients had no further
treatment. The median overall survival time, including
surgical patients, was 10.7 months for the observation
group and 10.9 for WBRT group (p = 0.89). The 2-year
local control rate (69% vs. 81%, p = 0.04) and 2-year dis-
tant control rate (52% vs. 67%, p = 0.023) were improved
by WBRT. Death caused by intracranial progression was
44% in the observation group and 28% in the WBRT
group. Salvage therapies, e.g. WBRT, had to be used
more frequently in the observation group [8]. Regarding
the health-related quality-of-life no sustained decline in
physical, role, and cognitive functioning were found. The
latest randomized trial described transient changes in
quality-of-life only [18].
In the retrospective analysis of the data base no differ-
ence was made between WBRT as an initial or salvage
treatment. Given the fact that patients with favorable
histology and stable extracranial disease were not dis-
tributed equally a selection bias cannot be excluded.
Under these circumstances the survival benefit for
WBRT has to be judged cautiously. Local control rates
were not documented.
The most common late toxicity for SRS is radiation
necrosis. In 21 patients (6.2%) radiation necrosis after
SRS was assumed in MRI. Radiation necrosis can be dif-
ficult to distinguish from tumor recurrence on MRI and
may require the use of surgery, positron emission tom-
ography (PET) or magnetic resonance spectroscopy
(MRS). In patients having neurologic symptoms max-
imum SUV and dynamic evaluation of FET-PET con-
firmed radiation necrosis in five individuals. AdditionalWBRT had no influence on the occurrence of radiation
necrosis. Due to low incidence in the study no predictive
factors for radiation necrosis were found. While the risk
of radiation necrosis after conventional radiotherapy is
highest in the first 2 years after treatment, appearance of
radiation necrosis after SRS can be as short as 3 months
[19]. In literature the incidence of brain necrosis varies
from about 5 – 32% [7,8,13,20-22]. Higher rate of necro-
sis occur with longer follow-up [14]. By using the pat-
tern of time–activity curve in FET-PET local brain
metastasis recurrence can be differentiated from radi-
ation necrosis with high accuracy [23]. Radiation dose,
tumor volume and radiation treatment planning factors
are predictive for radiation induced necrosis [12,24,25].
In RTOG 90–05 study tumor volume > 8.2 ml and a ra-
tio of maximum dose to prescription dose > 2 were sig-
nificantly associated with unacceptable toxicity [26]. The
only predictive parameter influencing the risk of radi-
ation necrosis described by Valery et al. was the con-
formity index [27].
Conclusions
SRS alone or in combination with WBRT is an effective
treatment for patients with 1–3 cerebral metastases;
however a small subset of patients may develop neuro-
logical complications. KPS and RPA class are relevant
prognostic factors for overall survival. Especially for pa-
tients with favorable features additional WBRT should
be considered without having increased rates of necrosis.
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